TAK-390MR is an investigational for the treatment of acid related disorders.. TAK-390MR employs a new modified release (MR) technology on an enantiomer of lansoprazole.
In addition, dexlansoprazole MR provided complete relief of heartburn symptoms for a median of 55% of 24-hour periods over 28 days in patients with symptomatic nonerosive GERD.
The safety profile of dexlansoprazole MR is similar to that of lansoprazole.
Because dexlansoprazole MR can be taken without regard to food or time of day it is more convenient for individuals who find compliance with meal-associated dosing of medication difficult or eat at irregular times.
The prolonged duration of acid suppression provided by dexlansoprazole MR addresses the short half-life of conventional PPI and offers a novel approach to extending gastric pH control in patients with selected acid-related disorders.